Please login to the form below

Not currently logged in
Email:
Password:

EC approves Pegasys

Roche has revealed that the European Commission approved its hepatitis C medicine, Pegasys. The company says the drug could lead to patients being cured in four months
Roche has revealed that the European Commission (EC) approved its hepatitis C medicine, Pegasys. The company says the drug could lead to patients being cured in four months.

It has been developed as a 16-week treatment for the genotype 2 and 3 strains of hepatitis C in patients with low virus levels. The company hopes that the shorter treatment rates will reduce patients' exposure to drug therapies.

Previous to the approval of Pegasys, patients had to undergo 24 weeks of treatment, even if they had low virus levels and rapid response rates to the medicine.

William Burns, CEO of Roche pharmaceuticals division, explained that the company is committed to advancing the use of personalised medicine, which accounts for patients' reaction and medical history.

"This approval for 16 weeks of treatment in genotype 2 and 3 patients with a rapid response demonstrates the value of using diagnostic tools to determine an individual treatment regime and hopefully will encourage more eligible patients to come forward for treatment," he said.

26th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics